MDRNA Inks Early-Stage Research Deal with Pfizer

Under the deal, Pfizer will evaluate MDRNA's proprietary siRNA constructs and delivery technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.